Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Brain is supposed to be the most complicated part of the body which is very far from the reach of drug moieties. The drug entry in to the brain region depends upon various factors, and among those, the blood-brain-barrier remains the most prominent one. This barrier restricts the entry of almost all the drug and most of the essential biological components like proteins, peptides, etc. and hinders treatment of the CNS disorders. Alzheimer Disease (AD) is one such brain disorder, more specifically a neurodegenerative disorder which primarily affects the older adults. AREAS COVERED: From solubility enhancement to targeted delivery, the nanoparticulate system became the answer for almost all the criticality related to drug delivery. Hence, nanoparticulate drug carrier system has been widely utilizing to remove the hurdles of brain drug delivery. Keeping this in mind, we have underlined the proficiencies of the nanocarrier systems which claim to improve the drug efficacy for the treatment of the AD. EXPERT OPINION: The nanotechnological approaches are highly exploited by the researchers to enhance the drug permeation across the BBB to improve its bioavailability and efficacy by protecting the drug from peripheral degradation. However, still in this area of drug targeting provides vast scope for discoveries towards the enhancement of drug efficacy through surface modifications, site specification, reduced toxicity of the nanocarrier system and so on.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“There are some drug molecules which selectively reduces the amyloid plaque formation like tarenflurbil [19], semagacestat (γ-secretase inhibitor) [20], solenezumab [21], and aducanumab (anti-Aβ antibody) [22] etc.”
BackgroundSaraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609 · cited 1×
“Polymeric nanoparticles Nanoparticle offers a most versatile and fortunate drug carrier system that can successfully deliver the active drug substance to a critical region of the body like brain [43,62].”
BackgroundDong, X.-X., Wang, Y., & Qin, Z.-H. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.24 · Cited by 1,297
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 1×
“This increase in bioavailability relates to the theory that coating of polysorbate 80 on NPs enhances the targeting ability [92,100] to a specific apolipoprotein B and E to facilitate the transfer of drug across the BBB via receptor-mediated endocytosis [101].”
BackgroundTau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037 · cited 1×
“It has been reported that nicotinamide, lithium, and valproate are the drugs which can reduce this hyperphosphorylation and maintain the neuronal health [26,27] (Figure 1(b)).”
BackgroundApolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801 · cited 1×
“This increase in bioavailability relates to the theory that coating of polysorbate 80 on NPs enhances the targeting ability [92,100] to a specific apolipoprotein B and E to facilitate the transfer of drug across the BBB via receptor-mediated endocytosis [101].”
BackgroundThe Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · cited 1×
“Latrepirdine is a drug that is used to target such mitochondrial abnormalities [28].”
BackgroundTransport of drugs across the blood–brain barrier by nanoparticles.
Wohlfart, S., Gelperina, S., & Kreuter, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.08.017 · Cited by 715 · cited 2×
“The blood brain barrier The AD early diagnosis and successful treatment are severely hindered owing to the existence of the BBB(8) [29].”
Background
Cited by
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Self-citationIntranasal drug delivery: opportunities and toxicologic challenges during drug development
Keller, L.-A., Merkel, O., & Popp, A. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00891-5 · Cited by 591
Nanoparticles in Drug Delivery: From History to Therapeutic Applications
Afzal, O., Altamimi, A. S. A., Nadeem, M. S., Alzarea, S. I., Almalki, W. H., Tariq, A., Mubeen, B., Murtaza, B. N., Iftikhar, S., Riaz, N., et al. (2022) · Nanomaterials · doi:10.3390/nano12244494 · Cited by 468
Overcoming barriers by local drug delivery with liposomes
Antimisiaris, S. G., Marazioti, A., Kannavou, M., Natsaridis, E., Gkartziou, F., Kogkos, G., & Mourtas, S. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.019 · Cited by 339
Self-citationStimuli-responsive In situ gelling system for nose-to-brain drug delivery
Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U., Kesharwani, P., Ravichandiran, V., Kumar, P., Naidu, V. G. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.044 · Cited by 298
Self-citation
Metadata
- Authors
- Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S.-D., Chougule, M., Shoyele, S. A., Gupta, U., Ajazuddin, & Alexander, A.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2018-05-17
- Volume
- 15
- Issue
- 6
- Pages
- 589-617
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2800592645
- Cited by
- 101
- References
- 36
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. https://app.cochat.ai/papers/10.1080/17425247.2018.1471058
- The paper
- Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S.-D., Chougule, M., Shoyele, S. A., Gupta, U., Ajazuddin, & Alexander, A. (2018). Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2018.1471058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.